Skip to main content

Table 3 Crude incidence of the 20 most common non skin cancers in both study arms

From: Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls

 

Controls (n = 2817) †

HHT (n =2161) ‡

 
 

Cancer cases

Cases per 100,000

SEM

Cancer cases

Cases per 100,000

SEM

p value

Bladder

9

320

106

12

5090

153

0.3

Brain

21

746

162

11

463

146

0.21

Breast

91

3230

333

80

3702

406

0.38

Cervical

14

497

133

11

463

146

0.86

Colorectal

56

1988

263

37

1712

279

0.47

Kidney

11

391

118

11

463

146

0.7

Leukemia

17

604

146

7

324

122

0.16

Liver

27

959

184

11

463

146

0.042

Lung

106

3763

359

38

1758

283

<0.0001

Lymphoma

19

675

154

16

740

185

0.79

Melanoma

67

2378

287

45

2082

307

0.48

Mesothelioma

1

36

36

0

0

0

0.38

Mouth

5

178

79

7

324

122

0.3

Myeloma

8

284

100

4

185

93

0.48

Oesophagus

9

320

106

4

185

93

0.35

Ovary

13

462

128

13

602

166

0.5

Pancreas

21

746

162

9

417

139

0.14

Prostate

56

1988

263

33

1527

264

0.22

Stomach

39

1384

220

14

648

173

0.012

Uterus

20

710

158

10

463

146

0.26

All cancers°

668

23713

800

398

22351

834

0.0012

  1. † The control arm represented 142 survey respondents and 2,675 reported relatives. ‡ The HHT arm represented 1,007 survey respondents and 1,154 reported relatives. Note that for stomach and pancreatic cancer, the higher than expected control values (Table 2) suggest that these primary cancers may not have been appropriately assigned by respondents and relatives. ° All cancers includes less common cancers. P value calculated by Mann Whitney.
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172